4-甲基-1-哌啶羧酸乙酯 | 90950-45-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-甲基-1-哌啶羧酸乙酯
• 英文名称: 4-Methyl-piperidin-carbonsaeure-(1)-ethylester
• 英文别名: Ethyl 4-methylpiperidine-1-carboxylate
• CAS: 90950-45-1
• 化学式: C₉H₁₇NO₂
• mdl: MFCD01353158
• 分子量: 171.239
• InChiKey: AILZEXMVCHHZDU-UHFFFAOYSA-N

物化性质

• 沸点：
  112 °C(Press: 20 Torr)
• 密度：
  0.997±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20100160280A1

  公开（公告）日：2010-06-24

  Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡啶和嘧啶化合物： 或者是根据说明书中定义的药用可接受盐，其中m、n、R1、R2、R3、R4、R5、R6、R7、X1、X2、X3、X4、X5、X6、X7、X8和Y都有所定义； 或者是根据说明书中定义的药用可接受盐，其中环A、m、n、y、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和环A都有所定义； 或者是根据说明书中定义的药用可接受盐，其中m、n、y、R2、R3、R4、R5、R6、R7、R9、X1、X2和环A都有所定义；含有它们的组合物以及制备这类化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• Modulators of muscarinic receptors
  申请人：Hurley J. Dennis

  公开号：US20060287303A1

  公开（公告）日：2006-12-21

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及肌氨酸受体调节剂。本发明还提供包含这种调节剂的组合物，以及用于治疗肌氨酸受体介导疾病的方法。
• [EN] NOVEL COMPOUNDS AS MODULATORS OF GPR-119<br/>[FR] NOUVEAUX COMPOSES UTILISES COMME MODULATEURS DE GPR-119
  申请人：RHIZEN PHARMACEUTICALS SA

  公开号：WO2012170867A1

  公开（公告）日：2012-12-13

  The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.

  本发明涉及公式（A）和（B）的新化合物作为GPR-119调节剂，其制备方法，含有它们的药物组合物，以及利用它们治疗、预防和/或改善GPR-119介导的疾病或疾病的方法。
• [EN] HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS<br/>[FR] DÉRIVÉS D'HÉTÉROARYLE SULTAME UTILISÉS EN TANT QUE MODULATEURS DE RORC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015104353A1

  公开（公告）日：2015-07-16

  (I) Compounds of the formula I or a pharmaceutical salt thereof, wherein m, n, q, r, A, W, X1, X2, X3, X4, Y,, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  化合物的公式I或其药用盐，其中m、n、q、r、A、W、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11的定义如本文所述。还公开了制备这些化合物的方法，以及将这些化合物用于治疗炎症性疾病如关节炎的方法。
• Benzimidazole derivatives
  申请人：——

  公开号：US20030236267A1

  公开（公告）日：2003-12-25

  This invention provides compounds which are represented by a general formula [I] 1 [in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3-10 membered aliphatic nitrogen-containing heterocyclic group; R 3 , R 4 and R 5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.

  这项发明提供了一些化合物，它们由一般式[I]1表示，其中X代表氢或卤素；B代表卤素、氰基或者可选的含氟低碳基；D代表一个3-10个成员的脂肪氮杂环基团；R3、R4和R5可能相同也可能不同，每个代表氢、可选的取代基的低碳基等；a为0或1。这些化合物表现出高亲和力对于痛觉受体，并抑制痛觉素的作用，因此可用作镇痛剂、抗肥胖剂、改善脑功能的药物、治疗阿尔茨海默病和痴呆症的药物、以及治疗精神分裂症、神经退行性疾病、抑郁症、尿崩症、多尿症、低血压等的治疗剂。